| Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients. | |
| | |
MedLine Citation:
|
PMID: 21441616 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study compared the effect of simvastatin on lymphocyte secretory function between patients with impaired glucose tolerance (IGT) (n=30) and mixed dyslipidemia (n=29). Lipid profile, glucose metabolism markers (fasting and 2-h post-glucose challenge glucose levels, HOMA-IR and glycated hemoglobin), plasma CRP levels and the release of interleukin-2 and interferon-γ by phytohemagglutinin-stimulated T lymphocytes were determined before and after 30 and 90 days of simvastatin administration (20 mg daily). Phytohemagglutinin-stimulated T cells from both IGT and mixed dyslipidemic subjects released significantly higher amounts of both cytokines than lymphocytes of 30 dyslipidemia-free individuals with normal glucose tolerance. Despite improving the lipid profile, simvastatin produced no effects on glucose metabolism markers in either treatment groups. The drug normalized the lymphocyte cytokine release and plasma hsCRP in mixed dyslipidemic patients but not in IGT patients. Our study indicates that the presence of mixed dyslipidemia and IGT is associated with the enhanced secretory function of human lymphocytes. Simvastatin is an effective lymphocyte-suppressing agent in mixed dyslipidemic patients but not in IGT patients. |
| | |
Authors:
|
Robert Krysiak; Bogusław Okopień |
Related Documents
:
|
17659416 - The sling lift: an ancillary procedure for malar rejuvenation. 10917136 - A measure of skin familiarity and its role in the early detection of skin cancer. 20379126 - Diabetes outpatient care before and after admission for diabetic foot complications. 18220646 - Treatment of diabetic foot ulcer: an overview strategies for clinical approach. 20482516 - Nf-kappab mediates lipid-induced fetuin-a expression in hepatocytes that impairs adipoc... 10582556 - Amelioration by krp-297, a new thiazolidinedione, of impaired glucose uptake in skeleta... |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pharmacological reports : PR Volume: 63 ISSN: 1734-1140 ISO Abbreviation: Pharmacol Rep Publication Date: 2011 |
Date Detail:
|
Created Date: 2011-03-28 Completed Date: 2011-07-18 Revised Date: 2011-11-28 |
Medline Journal Info:
|
Nlm Unique ID: 101234999 Medline TA: Pharmacol Rep Country: Poland |
Other Details:
|
Languages: eng Pagination: 95-101 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland. r.krysiak@interia.pl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Glucose
/
drug effects C-Reactive Protein / metabolism Cytokines / drug effects, metabolism Dyslipidemias / drug therapy* Female Glucose Intolerance / drug therapy* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology Lipids / blood Male Middle Aged Simvastatin / pharmacology* T-Lymphocytes / drug effects*, secretion |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Cytokines; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 79902-63-9/Simvastatin; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-? secretion in epileptic...
Next Document: Noradrenaline release in rodent tissues is inhibited by interleukin-1? but is not affected by uroten...